These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


343 related items for PubMed ID: 25370185

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Using acute tryptophan depletion to investigate predictors of treatment response in adolescents with major depressive disorder: study protocol for a randomised controlled trial.
    Stewart RM, Hood SD, Rao P, Moore JK, Runions KC, Murphy SE, Wong JWY, Zepf FD.
    Trials; 2018 Aug 10; 19(1):434. PubMed ID: 30097056
    [Abstract] [Full Text] [Related]

  • 4. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.
    Health Technol Assess; 2008 May 10; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of adolescent depression: what we have come to know.
    Vitiello B.
    Depress Anxiety; 2009 May 10; 26(5):393-5. PubMed ID: 19404989
    [No Abstract] [Full Text] [Related]

  • 10. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
    Chen Y, Cao X, Zang W, Tan S, Ou CQ, Shen X, Gao T, Zhao L.
    Trials; 2019 Jan 09; 20(1):34. PubMed ID: 30626424
    [Abstract] [Full Text] [Related]

  • 11. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
    Salaminios G, Duffy L, Ades A, Araya R, Button KS, Churchill R, Croudace T, Derrick C, Dixon P, Dowrick C, Gilbody S, Hollingworth W, Jones V, Kendrick T, Kessler D, Kounali D, Lanham P, Malpass A, Peters TJ, Riozzie D, Robinson J, Sharp D, Thomas L, Welton NJ, Wiles N, Lewis G.
    Trials; 2017 Oct 24; 18(1):496. PubMed ID: 29065916
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, Schatzberg AF, Gordon E.
    Trials; 2011 Jan 05; 12():4. PubMed ID: 21208417
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Schatzberg A, Roose S.
    Am J Geriatr Psychiatry; 2006 Apr 05; 14(4):361-70. PubMed ID: 16582045
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
    Petersen T, Harley R, Papakostas GI, Montoya HD, Fava M, Alpert JE.
    Psychol Med; 2004 Apr 05; 34(3):555-61. PubMed ID: 15259840
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 18.